Authors: Katarzyna MiziaStec Bartosz Lasota Magdalena Mizia Artur Chmiel Tomasz Adamczyk Jerzy Chudek Zbigniew Gasior
Publish Date: 2012/11/10
Volume: 28, Issue: 5, Pages: 613-619
Abstract
Copeptin is a new biomarker of cardiovascular diseases Its diagnostic value in degenerative aortic valve stenosis AS with preserved left ventricle systolic function is unknown We aimed to assess the association of serum copeptin levels with AS severity and coexistence of coronary artery disease CAD Sixtyfour patients with AS and preserved left ventricle systolic function including 40 with severe degenerative AS group sAS effective orifice area EOA = 067 cm2 and 24 with moderate degenerative AS group mAS EOA = 140 cm2 were enrolled into the study Twentythree patients without AS and heart failure matched for age sex and CAD occurrence served as the control group group C Serum levels of copeptin and Nterminal probrain natriuretic peptide NTproBNP were measured using enzymelinked immunosorbent assay The mean serum copeptin concentrations were significantly higher in patients with AS sAS 405 pg/ml and mAS 351 pg/ml sAS vs mAS P 005 compared with group C 302 pg/ml P 005 Serum copeptin levels correlated inversely with EOA r = −055 P 0001 in AS patients There was no correlation between copeptin and NTproBNP or association with the coexisting CAD Receiveroperating characteristics analysis showed that copeptin was a good marker of severe/moderate AS sensitivity 71 specificity 87 with the optimized cutoff value of 354 pg/ml Serum copeptin concentration constitutes a novel biomarker of degenerative AS Coexisting CAD does not interfere with copeptin level
Keywords: